



Allergic Reactions to Current Available COVID-19 Vaccines

Guest Editors:

Dr. Francesca Puggioni

Personalised Medicine Clinic
Asthma & Allergy, Humanitas
University, Department of
Biomedical Sciences, IRCCS
Humanitas Research Hospital,
Rozzano, 20089 Milan, Italy

francesca.puggioni@
humanitas.it

Dr. Enrico Marco Heffler

Personalised Medicine Clinic
Asthma & Allergy, Humanitas
University, Department of
Biomedical Sciences, IRCCS
Humanitas Research Hospital,
Rozzano, 20089 Milan, Italy

enrico.heffler@hunimed.eu

Deadline for manuscript
submissions:

1 May 2022

Message from the Guest Editors

Adverse hypersensitivity reactions to SARS-CoV-2 vaccines for the prevention of Coronavirus disease 2019 (COVID-19) have been reported since the initiation of the global vaccination campaign. These cases have elicited a lot of clamor, prompting the necessity to determine the real prevalence of allergic reactions to the vaccines, especially because no cases of anaphylaxis were reported in randomized clinical trials with the vaccine. A large number of studies have been published in the latest months about this topic, confirming that hypersensitivity reactions to COVID-19 vaccines and their prevention are one of the hot topics in the allergy and clinical immunology field.

The underlying immunological mechanisms of hypersensitivity reactions to the COVID-19 vaccines are only partially understood and urgently need clarification.

Precisely for these reasons, this Special Issue will focus on the re-assessment of published evidence and the re-evaluation of procedures and protocols for the prevention and management of this specific aspect, also taking into consideration patients' psychological aspects and new tools such as digital health technologies.





Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious
Diseases, College of Veterinary
Medicine, University of Georgia
Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access:— free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [Embase](#), [CAPlus / SciFinder](#), and many [other databases](#).

Journal Rank: [JCR - Q2 \(Immunology\)](#)

Contact Us
